Safety of antifibrotic drugs in idiopathic pulmonary fibrosis patients awaiting lung transplantation
R. Chirinos Guevara (barcelona, Spain), E. Vélez (barcelona, Spain), C. Berastegui (barcelona, Spain), A. Villar (barcelona, Spain), E. Revilla (barcelona, Spain), H. Sintes (barcelona, Spain), B. Sáez (barcelona, Spain), M. López Meseguer (barcelona, Spain), C. Bravo (barcelona, Spain), V. Monforte (barcelona, Spain), A. Roman (barcelona, Spain), I. Bello (barcelona, Spain), J. Sacanell (barcelona, Spain)
Source: International Congress 2018 – Moving lung transplantation forward
Session: Moving lung transplantation forward
Session type: Thematic Poster
Number: 2586
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Chirinos Guevara (barcelona, Spain), E. Vélez (barcelona, Spain), C. Berastegui (barcelona, Spain), A. Villar (barcelona, Spain), E. Revilla (barcelona, Spain), H. Sintes (barcelona, Spain), B. Sáez (barcelona, Spain), M. López Meseguer (barcelona, Spain), C. Bravo (barcelona, Spain), V. Monforte (barcelona, Spain), A. Roman (barcelona, Spain), I. Bello (barcelona, Spain), J. Sacanell (barcelona, Spain). Safety of antifibrotic drugs in idiopathic pulmonary fibrosis patients awaiting lung transplantation. 2586
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: